Evidence map›Paper›PMID 25878352›Full record

ArticleJournal of clinical microbiology2015

Improved Standardization of the Bio-Rad Platelia Aspergillus Galactomannan Antigen Sandwich Enzyme Immunoassay Using the DS2 (Dynex) Enzyme-Linked Immunosorbent Assay (ELISA) Processing System.

R L Gorton, P L White, E Bagkeris, D Cotterall, R Desai, T McHugh, C C Kibbler

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. β-d-Glucan andMedical journal, Armed Forces India · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

R L GortonUK Clinical Mycology Network (UKCMN) Regional Laboratory, Department of Microbiology, Royal Free Hospital, Hampstead, London, United Kingdom rebecca.gorton@nhs.net.
P L WhiteUKCMN Regional Laboratory, Public Health Wales, Microbiology Cardiff, UHW, Cardiff, United Kingdom.
E BagkerisPopulation, Policy & Practice Program, UCL Institute of Child Health, London, United Kingdom.
D CotterallUK Clinical Mycology Network (UKCMN) Regional Laboratory, Department of Microbiology, Royal Free Hospital, Hampstead, London, United Kingdom.
R DesaiUK Clinical Mycology Network (UKCMN) Regional Laboratory, Department of Microbiology, Royal Free Hospital, Hampstead, London, United Kingdom.
T McHughCentre for Clinical Microbiology, UCL, Royal Free Campus, London, United Kingdom.
C C KibblerUK Clinical Mycology Network (UKCMN) Regional Laboratory, Department of Microbiology, Royal Free Hospital, Hampstead, London, United Kingdom.
University College London · GBThe Royal Free Hospital · GBPublic Health Wales · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The galactomannan enzyme immunoassay (GM-EIA) is widely utilized for the diagnosis of invasive aspergillosis (IA). There is inconsistent reproducibility of results between centers when the assay is processed manually. Automation of EIAs can reduce variation. This study investigated the semiautomation of the GM-EIA on the DS2 (Dynex) platform in the following three stages: (i) DS2 GM-EIA method validation with experimental samples, (ii) DS2 retesting of case-defined clinical samples, and (iii) a 12-month audit of DS2 GM-EIA performance. In stage i, Bland-Altman analysis demonstrated a reduced variance between optical density index (ODI) values for samples processed on two DS2 platforms (mean difference, -0.02; limits of agreement [LOA], -0.19 to 0.14) compared with the variance between samples processed manually and on a DS2 platform (mean difference, 0.02; LOA, -0.25 to 0.3). In stage ii, 100% (14/14 samples) qualitative agreement was observed for serum samples from patients with IA, with no significant change in the ODI values when samples were processed on the DS2 platform. A significant decrease in ODI values was observed for control serum samples on the DS2 platform (difference, 0.01; P = 0.042). In stage iii, a significant reduction in the frequency of equivocal results, from 5.56% (136/2,443 samples) to 1.56% (15/961 samples), was observed after DS2 automation (difference, 4.0%; 95% confidence interval [CI], 2.7 to 5.2%; P < 0.01), with an equivalent increase in negative results. This study demonstrates that GM-EIA automation may reduce intersite variability. Automation does not have an impact on the repeatability of truly positive results but contributes to a reduction in false-positive (equivocal) GM-EIA results, reducing the need to retest a significant proportion of samples.

Indexed as

Antigens, FungalAspergillusAutomation, LaboratoryDiagnostic Tests, RoutineGalactoseHumansImmunoenzyme TechniquesInvasive Pulmonary AspergillosisMannansReference StandardsReproducibility of ResultsAntigens, FungalgalactomannanGalactoseMannans

Identifiers

PMID25878352
PMCPMC4473217
OpenAlexW1855733489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.